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ABSTRACT 
PGC-1 coactivators are central regulators of several cellular processes, most notably the 
coupling between energy demands and supply. PGCs activate distinct biological processes 
in a tissue-specific manner. These include mitochondrial biogenesis, oxidative 
phosphorylation, oxygen transport, gluconeogenesis, angiogenesis, and muscle fiber-type 
specification. The family consists of three members: PGC-1α, PGC-1β, and PRC, among 
which the most studied is PGC-1α. Transcription of a single PGC-1α	 gene produces 
different isoforms (e.g. PGC-1α1 to α4) with different biological functions. All of the PGC-
1α isoforms share some domain similarity but PGC-1α2, α3 and α4 lack the C-terminal 
domains present in PGC-1α1. The actions of PGC-1α1 are strongly linked to energy 
metabolism, whereas PGC-1α4 regulates skeletal muscle hypertrophy. The functions of 
PGC-1α2 and PGC-1α3 have remained unknown.  
To study the mechanism of action of the new PGC-1α isoforms, we performed a protein 
complex purification and identified protein partners of all PGC-1α variants. We found that 
all PGC-1α isoforms can function as positive regulators of transcription by associating with 
members of the Mediator complex, histone acetyltransferase complexes, and splicing 
factors. Furthermore, we identified several transcription factors associated with each PGC-
1α isoform, which allowed us to predict how different target genes are regulated. 
Interestingly, we also observed that PGC-1α isoforms can regulate splicing events and can 
affect the exon composition of their corresponding target transcripts.  
Here, we report for the first time that PGC-1α1 can dimerize with other PGC-1α isoforms, 
suggesting that some of the functions of PGC-1α might be mediated by heterodimers.  
Since PGC-1α1 is a key modulator of cellular metabolism in several tissues, it has gained 
considerable attention as potential target for the treatment of metabolic disorders. For that 
reason, we developed a screening platform to identify chemicals that can induce PGC-1α1 
protein accumulation. From this screen, we identified several candidate small molecules as 
potential PGC-1α1 activators, which were validated in brown adipocytes. We identified 4 
compounds that can increase PGC-1α1 protein accumulation, target gene expression, and 
mitochondrial respiration. These compounds could represent the beginning of a new class 
of therapeutics against obesity and related disorders. 
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1 INTRODUCTION 
 
1.1 TRANSCRIPTIONAL REGULATION IN EUKARYOTIC CELLS 
Transcription is the process by which specific parts of the DNA sequence are copied into 
RNA, thus leading to gene expression. This process is tightly regulated in eukaryotic cells 
to ensure that gene expression is according to cell requirements and environmental signals. 
Transcriptional regulation is coordinated by a myriad of proteins such as transcription 
factors (TF), chromatin modifying and remodeling complexes and coregulators 
(coactivators or corepressors). In addition, transcription involves specific DNA sequences 
such as promoters and enhancers.  
One of the essential requirements for transcription is the presence of an RNA polymerase 
(RNApol) enzyme. Mammalian eukaryotic cells have 3 classes of RNApol that are 
responsible for transcribing different types of genes. RNApol I transcribes large ribosomal 
RNA genes. Protein coding genes and some small RNAs are transcribed using RNApol II. 
RNApol III transcribes tRNA, 5S RNA and other small structural RNA [1-3]. Initially, 
gene expression depends on the assembly of a pre-initiation complex (PIC) containing one 
of the mentioned RNA polymerases on the core promoter region. Each RNApol has 
specific general initiation factors that contribute to accurate initiation of transcription from 
a core promoter region. PICs are assembled by several general transcription factors (GTFs) 
[4] to start transcription from the correct position on the promoter region [5-7].  
A second level of transcriptional regulation is mediated by a large number of proteins 
called TFs that recognize and bind to specific DNA sequences located in the regulatory 
regions. These TFs express and activate in response to special environmental cues and lead 
to inhibition or increase in the expression of their specific target genes [8]. The third group 
of transcriptional regulators exerts their role in a DNA-binding independent manner. These 
proteins are called coactivators or corepressors depending on if they activate or repress 
transcription, respectively. These proteins affect gene expression through remodeling 
chromatin structures/modifying histones or they affect pre-initiation complex formation and 
function [7, 9].  
 
1.1.1 Transcription by RNA polymerase II 
RNApol II is a protein complex with ability to perform RNA synthesis and also 
proofreading of the nascent transcript [1]. The first step in transcription by RNApol II is 
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binding to sequence specific promoter region by the action of the Transcription Factor IID 
(TFIID) complex, component of the PIC. TFIID contains the TATA-binding protein (TBP) 
and 13 TBP-associated factors, which bind to TATA element in the promoter. This leads to 
a bend in DNA that acts as a platform for PIC assembly [10, 11]. Later binding of TFIIB 
stabilizes the interaction of TFIID to the DNA on the TATA element and this complex is 
further stabilized by TFIIA binding [12]. Moreover, TFIIB joining to the complex leads to 
the addition of RNApol II in association with TFIIF to the PIC and it helps in positioning 
the active site of RNApol II at the transcription start site (TSS) [13]. Binding of TFIIE and 
consequently TFIIH will complete assembly of the PIC [14], which modulate promoter 
melting (opening DNA duplex on the promoter region) with ATP-dependent helicase 
activity of TFIIH [15-17] that leads to formation of an open complex between DNA and 
RNApol II. Finally, in the presence of all nucleotide triphosphates (NTPs), RNApol II is 
able to clear the promoter and enters the transcription elongation phase [18] (Figure 1). 
 
Figure 1. Schematic model for the regulation of PIC assembly and regulation of transcription 
by RNApol II. Assembly of a PIC including RNApol II and general transcription factors on the 
TATA element of the core promoter. PIC assembly and function is regulated sequentially by 
binding of regulatory factors to distal regulatory regions on the DNA, binding of chromatin 
remodeling complexes and histone modifying factors to modify chromatin structure and finally, 
binding of other regulatory factors that facilitate function of the general transcription machinery. 
(Adapted from Robert G. Roeder, 2005, FEBS letters)  
 
1.1.2 Transcriptional coregulators 
Transcriptional coregulators are proteins that can directly cooperate with the transcription 
machinery and increase (coactivators) or decrease (corepressor) the levels of gene 
TFIID (core promoter recognition)
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expression. This group of proteins might have enzymatic activity to change chromatin 
structure or they might act as a scaffold and provide a regulatory platform for binding of 
chromatin modifiers and transcriptional machinery [19].  
 
Histone modifying and chromatin remodeling complexes 
Eukaryotic genomic DNA is organized in a compact chromatin structure that is not readily 
accessible to the general transcription machinery. Several protein complexes contribute to 
regulating DNA accessibility for gene expression. These protein complexes exert their 
function by remodeling chromatin or through chromosomal histone modifications. All of 
these modifications alter the accessibility of DNA for binding of activators or repressors 
and further gene regulation. Histone modifying enzymes are a group of enzymes that 
modulate gene expression by mediating covalent acetylation, methylation, or ubiquitylation 
of lysine residues, methylation of arginine residues, and phosphorylation of serine and 
threonine residues at N-terminal regions of histones [20]. Among proteins with functional 
histone acetyltransferase activity (HAT) are CREB-binding protein CBP [21], the E1A 
binding protein p300 [22], and the p300/CBP-associated factor p/CAF [23]. Protein 
arginine methyltransferase PRMT1 [24] and histone deacetylase proteins (HDAC) such as 
GCN5 [25] are other examples of histone modifying enzymes that regulate gene expression 
through interaction with different transcription factors. ATP-dependent chromatin 
remodeling complexes such as SWI/SNF complex are the second group that can increase or 
decrease the accessibility of DNA for gene regulation [9]. These proteins mobilize 
nucleosomes to facilitate access of the transcription machinery and regulators to DNA [26]. 
SWI/SNF complex has been shown to be important for ligand-dependent activation of 
transcription by nuclear receptors [27]. 
 
Mediator Complex 
Another important coactivator complex necessary for the expression of protein-coding 
genes is the mediator complex. The human mediator complex was initially identified as a 
thyroid hormone receptor-associated protein (TRAP) [28]. Since then, several structural 
and functional studies have elucidated how the mediator functions in the control of 
transcriptional activation and repression. The mediator complex facilitates transcription by 
making a bridge between gene-specific transcription factors bound to specific regulatory 
elements on DNA and RNApol II in the PIC complex [29, 30]. The mediator also 
 4 
participates in releasing RNApol II from the promoter and transition from initiation to 
elongation process by stimulating phosphorylation of the C-terminal domain (CTD) of 
RNApol II [31]. Disturbances in mediator function have been associated with several 
diseases including cancer, metabolic and neurological disorders and cardiovascular diseases 
[32].  
  
1.2 SPLICING 
Several processes convert nascent transcript into mature RNA including 5’cap, RNA 
splicing and polyadenylation at 3’ end of the mRNA molecule. These three processing 
reactions can occur coupled with transcription. RNA splicing was discovered in 1977 [33, 
34] and is one of the main steps to generate a mature mRNA in a eukaryotic system. This 
process involves the removal of intron sequences and joining exon sequences together. 
Splicing events have been characterized in different systems and happen through the 
excision of intron sequences at the conserved splicing sites found on the 5’(GU 
dinucleotide) and 3’ (AG dinucleotide) end of introns [35]. In eukaryotes, the pre-mRNA 
splicing site recognition and the splicing reaction are catalyzed by the spliceosome 
complex. This complex is composed of small nuclear ribonucleoproteins (snRNPs) U1, U2, 
U4, U5, U6 and auxiliary factors including U2AF65 and U2AF35. All these proteins (with 
the help of RNA-dependent ATPases and helicases) lead to two steps of esterification and 
removal of intron sequence (cutting and sewing on the splice sites) [36]. 
Alternative splicing is the process that generates multiple mRNAs from a single gene and 
was discovered together with splicing [33, 34]. Alternative splicing increases the capacity 
of the eukaryotic genome to generate more proteins (protein isoforms with different peptide 
sequences, chemical and biological activities) from a single gene [37]. The presence of 
weak or strong splicing sites can result in different modes of alternative splicing (use of 
alternative 5’ splice site or alternative 3’ splice site and inclusion of alternative cassette 
exon). Alternative splicing can also happen through alternative polyadenylation sites or 
transcription initiation at different promoters. Most of the studies have focused on cis-
acting elements on the mRNA and trans-acting regulatory proteins that bind to these 
sequences to increase or silence the usage of adjacent splicing sites but it also has been 
shown that more than half of human genes have alternative promoters [38]. All of the 
mentioned mechanisms of alternative splicing contribute to protein diversity. Differences in 
peptide sequences can alter post-translational modifications, protein stability, localization, 
ligand binding, allosteric regulation and enzymatic activity and finally lead to different 
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cellular and developmental regulation. Misregulation of alternative splicing is linked to 
diseases such as cancer and developmental disorders [39]. 
 
1.3 THE PGC-1 FAMILY OF TRANSCRIPTIONAL COACTIVATORS 
Proteins of the (PGC-1) family of coactivators are main components in the regulation of 
energy metabolism in many tissues, often in response to higher energy demands. The first 
member of the PGC-1 family, PGC-1α, was identified in the late 1990s in brown adipose 
tissue as a key regulator of genes involved in cold-induced thermogenesis [40]. Since then, 
from PGC-1α DNA sequence and protein homology searches, PGC-1β and PRC (PGC-1-
related coactivator) joined the PGC-1 family [41, 42]. These proteins have high homology 
in structural features and share some biological activities, such as the ability to regulate 
mitochondrial biogenesis in different tissues. Since PGCs do not have a DNA-binding 
domain they exert their biological functions through interaction with transcription factors 
and other coactivator complexes. Most PGC-1s exert their biological function through a 
few shared protein domains among them (Figure 2). 
 
 
Figure 2. Schematic representation of the PGC-1 family members homology. Homology in 
PGC-1α, PGC-1β, and PRC structures. They all share Activation, Arg/Ser- rich domain (RS), and 
RNA recognition motif (RRM). The Repression domain is only present in PGC-1α and PGC-1β. 
(Adapted from Lin J, 2005, Cell Metabolism). 
 
Among this family of coactivators, PGC-1α has been especially studied in different 
research areas such as energy metabolism, cardiovascular disease, neurodegenerative 
diseases, skeletal muscle physiology, and even mood disorders. Many studies have 
determined the functions of PGC-1 family in different physiological and disease conditions, 
thus elucidating some of the underlying mechanisms by which these transcriptional 
regulators modulate cellular adaptation to different challenges (Figure 3).  
40%
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Figure 3. Skeletal muscle PGC-1s orchestrate systemic adaptations to physiological cues.  
Different PGC-1 proteins activate specific gene programs to regulate cellular adaptation to diverse 
challenges. They regulate fuel supply, uptake and utilization. (Adapted from Correia et al, 2015, 
Trends in endocrinology and metabolism) 
 
Since PGC-1α gene can be transcribed into multiple splice variants (please see 1.3.3), we 
refer to the canonical transcript as PGC-1α1. PGC-1α1 is a highly regulated coactivator 
whose activity and expression can be regulated by diverse stimuli in a tissue-specific 
manner. These include cold exposure in brown adipose tissue (BAT), fasting in liver, and 
exercise in skeletal muscle (among others). However, while in skeletal muscle PGC-1α1 is 
involved in fiber type switching toward more oxidative phenotype [43, 44], in brown and 
beige adipose tissue it induces adaptive thermogenesis and energy release in the form of 
heat [40]. Therefore, increased PGC-1α1 levels in either tissue could potentially have 
positive effects on whole body metabolism. The key role of PGC-1α1 in fuel handling 
makes this protein an interesting target in the treatment of type 2 diabetes, obesity, or any 
disorders associated with skeletal muscle wasting [45-48]. In fact, transgenic animals with 
skeletal muscle-specific PGC-1α1 overexpression are protected from muscular atrophy, 
diet-induced obesity, age-related sarcopenia, and insulin resistance [49]. Adipose-specific 
PGC-1α genetic deletion disturbs the mitochondrial and thermogenic gene networks, which 
makes those mice more prone to high-fat diet-induced insulin resistance [50]. Reduced 
PGC-1α1 levels have been reported in skeletal muscle and adipose tissue of diabetic 
patients, which could contribute to the pathogenesis of the disease [51]. Finally, PGC-1α1 
has also been implicated in the detoxification of reactive oxygen species (ROS) [48] and 
protection against neurodegenerative disorders like Huntington’s and Alzheimer’s diseases 
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and also amyotrophic lateral sclerosis (ALS) [52, 53]. 
The tissue expression profile of PGC-1β is similar to PGC-1α but its expression is not 
regulated by the same signals as PGC-1α. For instance, PGC-1α induces hepatic 
gluconeogenesis during fasting, while PGC-1β induced upon fasting modulates hepatic 
lipogenesis [54]. 
The function of PRC has been studied in vitro and the role of PRC seems to be limited to 
the regulation of mitochondrial biogenesis in amplifying cells [55]. The main problem of 
studying the role of PRC in vivo is that disruption of the PRC-encoding gene, results in 
embryonic lethality. Other functions recently described for the PGC-1 family include lipid 
synthesis, lipoprotein secretion, angiogenesis, hematopoiesis and immune response [56].  
 
1.3.1 Structure and modes of action 
PGC-1 coactivators exert their role in transcriptional regulation via interaction with a 
variety of transcription factors (such as nuclear receptors) and other coactivators. As many 
other coactivators, this family of proteins does not have a DNA-binding domain. Thus, they 
work as a docking platforms for other proteins with, for example, histone acetyltransferase 
activity or involved in the assembly of the basal transcription machinery [56]. In this 
manner, they facilitate pre-initiation complex formation to efficiently regulate gene 
expression. The protein domain organization of PGC-1 coactivators is remarkably similar, 
which describes the partial overlap in their physiological functions [57]. All three members 
share structural domains in their N- and C-terminal regions. Their N-terminal region 
includes a highly conserved activation domain that is an interaction surface for the 
recruitment of histone acetyltransferase proteins, such as the SRC-1 (Steroid Receptor 
Coactivator-1)/p300 complex (Figure 4) [58]. The activation domain includes several 
leucine-rich LXXLL motifs, also called NR (Nuclear Receptor) boxes, which mediate 
association of PGC-1s with the ligand-binding domain of a variety of nuclear hormone 
receptors [42, 59]. Following the activation domain, PGC-1α has a repression domain that 
interacts with P160 and Sirt1 (Sirtuin 1). These factors regulate PGC-1α’s biological 
activity.  
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Figure 4. Protein complexes associated with PGC-1α1. PGC-1α1 binds to different protein 
partners through several domains in its structure. PGC-1α1 binds to the histone acetyltransferase 
(HAT) and TRAP/DRIP/Mediator complexes through the amino and carboxyl termini, respectively. 
SIRT1 (Sirtuin 1) and P160 bind to the repression domain, which also contains three p38 MAP 
kinase phosphorylation sites (P). LXXLL and LLXXL motifs are nuclear receptor binding sites. 
Splicing factors bind to RNA binding domain in C-terminus. GR (Glucocorticoid Receptor), HNF-
4α (Hepatocyte Nuclear Factor-4α), PPARγ (Peroxisome Proliferator-Activated Receptor γ), ERR-α 
(Estrogen-related Receptor α), NRF-1 (Nuclear Respiratory Factor-1), MEF2C (Myocyte-specific 
Enhancer Factor 2C), FOXO1 (Forkhead Box O1). 
 
The greatest structural similarity between the three PGC-1 coactivators is at the carboxy-
terminal region [60, 61]. All three C-termini contain an RNA recognition motif (RRM) 
similar to the one found in SR proteins and heterogeneous nuclear ribonucleoproteins, 
which are known to mediate RNA binding. They also share an arginine-serine rich (RS) 
domain [40], before the RRM domain, which is typical of proteins involved in mRNA 
splicing [62]. The presence of RS and RRM domains in PGC-1 proteins suggests that they 
can be involved in RNA processing. Indeed, PGC-1α1 mutants that lack the RS and RRM 
domains cannot bind some splicing factors and therefore cannot regulate splicing processes 
in an in vitro system. This evidence suggests that PGC-1α1 exerts its function not only by 
quantitative regulation of gene expression, but also by coupling transcription and mRNA 
splicing [63]. It has been previously reported that the C-terminal region of PGC-1α1 is 
necessary for interacting with the mediator complex and the transcriptional apparatus 
through TRAP220/MED1 (Mediator of RNA polymerase II transcription subunit 1) [58]. 
The C-terminal region of PGC-1 proteins includes also two other highly conserved motifs 
with unknown function. One of them consists of a “DHDY” motif, which has been 
described as a binding site for the host cell factor (HCF) transcription factor. HCF acts in a 
complex with O-GlcNAc transferase to regulate PGC-1α1 stability during gluconeogenesis 
by inhibiting ubiquitylation of PGC-1α1 [64]. In addition, the C-terminus of PGC-
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1  proteins is the interaction site for other transcription factors such as MEF-2C (Myocyte 
enhancer factor-2C) [43, 65], YY1 (Ying yang 1) [66, 67], and FoxO1 (Forkhead box O1) 
[68] as well as some coregulators such as BAF60 (BRG1 associated factor 60a) [69]. 
 
1.3.2 Regulation of PGC-1α activity  
Most of the gene networks regulated by PGC-1α encode proteins involved in 
bioenergetically demanding metabolic pathways. The activation or inhibition of PGC-1α 
during these programs results in cellular adaptations to higher energy demands in response 
to tissue-specific physiological signals. Hence, it is important that cells keep a tight control 
over PGC-1α de novo synthesis, protein stability, and transcriptional activity. Many of 
these mechanisms are activated when BAT induces PGC-1α in response to cold exposure 
[40, 70, 71]. Among the signaling pathways that modulate PGC-1α1  gene expression some 
of the most well-characterized involve calcium-signaling [72], calcineurin A [65], cyclic 
AMP [73], and AMP-activated protein kinase (AMPK) [74]. In response to activation of 
these pathways several members of the nuclear receptor family, tissue-specific transcription 
factors, and other coactivators will be recruited to regulatory regions surrounding the PGC-
1α gene [57]. Epigenetic modifications such as DNA methylation can limit the 
transcriptional regulators’ approach to the proper genomic regions and thus interfere with 
the modulation of gene expression [75]. Some studies have reported the effects of PGC-1α 
promoter methylation on PGC-1α expression in different physiological and pathological 
situations. PGC-1α promoter methylation is decreased by physical exercise, a typical 
inducer of PGC-1α expression in skeletal muscle [76]. In contrast, increased PGC-1α 
promoter methylation has been identified in pathological situations linked with decreased 
level of PGC-1α expression [77, 78].  
Post-translational modifications play a prominent role in modulating the activity of PGC-
1α. These modifications include phosphorylation, acetylation, and ubiquitylation. Although 
this is not fully understood, the combination of different phosphorylation events seems to 
result in a code that ultimately regulates the biological activity of PGC-1α1. AMPK [79], 
p38 mitogen activated protein kinase (p38MAPK) [80], S6 kinase [81], protein kinase B 
[82], and glycogen synthase kinase 3b (GSK3b)  [83] are among kinases that regulate PGC-
1α1 activity. Phosphorylation by these kinases dictates association of PGC-1α1 with 
specific transcription factors or other coregulators [57]. The acetylation of PGC-1α1 can be 
altered by acetyltransferases such as GCN5 (General control of amino acid synthesis 
protein 5-like 2) [25] or deacetylases like Sirt1 [84, 85]. Deacetylation by Sirt1 results in 
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activation of PGC-1α1, while acetylation by GCN5 represses PGC-1α1 activity. It has been 
shown that selective chemical inhibition of PGC-1α  acetylation by GCN5 can ameliorate 
insulin sensitivity and thus reduce blood glucose in type 2 diabetic mice. This process 
happens through inhibition of interaction of PGC-1α  with HNF-4α and activation of 
gluconeogenesis in liver [86]. In addition,  PGC-1α  stability and cellular localization can 
be modified with other post-translational modifications. Ubiquitylation by specific E3 
ligases such as RNF34 and SCFFbw7 directly regulates PGC-1α  protein stability [83, 87, 
88]. Moreover, two studies have reported mitochondrial localization of PGC-1α  in a 
complex with SIRT1 and TFAM (mitochondrial transcription factor A) [89, 90]. 
Mitochondrial localization of PGC-1α  suggests that it could directly coordinate the 
transcription of nuclear-coding genes and mitochondrial genomes, to control mitochondrial 
biogenesis. In summary, all these events occur to ensure that cells under a particular 
physiological circumstance can have the correct PGC-1α activity to quickly adapt to the 
new biological situations. 
 
1.3.3 PGC-1α variants 
To date, numerous studies on PGC-1α structure and function have been performed on the 
mouse 797-amino acid long protein. It has been recently shown that transcription of the 
PGC-1α gene can be regulated by distinct promoter regions [91-94]. The use of several 
tissue-specific PGC-1α gene promoters coupled with alternative splicing leads to 
expression of several transcript and protein variants, which have diverse structure and 
function [95, 96]. Alternative splicing is a universal phenomenon which results in the 
production of distinct mRNAs from multi-exonic genes [97]. Our lab has originally 
identified and continues to focus on three of these variants known as PGC-1α2 through 
PGC-1α4 [96].  
PGC-1α1 is the most well-known isoform and is expressed from the previously identified, 
canonical gene promoter [65]. Alternative promoter usage results in the expression of PGC-
1α2, α3, and PGC-1α4. PGC-1α2 and α3 have different first exons but similar remaining 
exon/intron structure. This results in the expression of two distinct proteins with different 
N-terminal but overall similar domain structure (Figure 5). Moreover, PGC-1α2 is 379 
amino acids long with 41.9 kDa predicted molecular weight while PGC-1α3 is 370 amino 
acids long and has a predicted molecular weight of 41.0 kDa. In their structure they 
maintain part of PGC-1α1’s activation and repression domains and completely lack all the 
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C-terminal motifs of PGC-1α1 (i.e., the RS and RRM motifs) [96]. Despite PGC-1α4 
having the same alternative exon1 with PGC-1α2, it transcribes to a different mRNA 
structure (Figure 5). In fact, PGC-1α4 contains a premature stop codon induced by the 
insertion of a 31-nucleotide between exons 6 and 7. As a consequence, PGC-1α4 has a 
predicted molecular weight of 29.1 kDa, encoded by a 266 amino acid protein [96]. As 
PGC-1α2 and α3, PGC-1α4 also lacks all the C-terminal motifs of PGC-1α1 [94]. 
 
Figure 5. Members of PGC-1α family. Three newly identified PGC-1α isoforms are expressed 
from an alternative gene promoter. All new PGC-1α isoforms lack the C-terminus motifs of PGC-
1α1 but retain part of the activation and repression domains. 
 
Induction of PGC-1α2 and PGC-1α3 by physical exercise has been reported to be 
associated with VEGF (Vascular endothelial growth factor) expression and promotion of 
estrogen-related receptor (ERR)α-dependent angiogenesis [93]. Surprisingly, PGC-1α4 
expression in skeletal muscle leads to robust muscle hypertrophy [96] by upregulation of 
IGF-1 (Insulin-like growth factor-1) expression, which regulates muscle mass [98] and 
decreasing myostatin level, a negative regulator of muscle growth [99, 100]. Moreover, 
high expression of PGC-1α4 levels in mouse skeletal muscle causes resistance to cancer-
cachexia and disuse-induced atrophy [96]. In addition, hypoxia activates skeletal muscle 
PGC-1α4 to increase angiogenesis through ERRα and increase in VEGF gene transcription 
[101]. The mechanism of action of PGC-1α4 still needs to be further elucidated. The 
biological functions of PGC-1α2 and PGC-1α3 are under investigation. 
Changes in the expression of different PGC-1α coactivators in skeletal muscle can have 
several systemic consequences with even crosstalk between skeletal muscle and other 
tissues (Figure 3) [56]. Recently, several studies report that elevating specific PGC-1α 
variant in skeletal muscle can affect other tissues by secreting circulating factors 
(myokines). Among these myokines are irisin and BAIBA (β-aminoisobutyric acid) [102], 
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both under PGC-1α1 control, and the PGC-1α4-regulated myostatin and meteorin-like 
proteins [103, 104]. These molecules are secreted from skeletal muscle, transferring 
specific metabolic signals to, for example, adipose tissue. In this manner, overexpression of 
either PGC-1α1 or PGC-1α4 in skeletal muscle results in browning of adipose tissue 
through diverse mechanisms and pathways. Furthermore, we have recently reported that 
activation of skeletal muscle PGC-1α1 can protect from stress-induced depression [105] by 
skeletal muscle detoxification of the tryptophan metabolite kynurenine, which is converted 
to kynurenic acid. Moreover, Mills et al [106] show that skeletal muscle transduction with 
PGC-1α1 isoform but not PGC-1α4 stimulates secretion of neurturin, which is sufficient 
and necessary to increase NMJ formation and size. Neurturin was identified as a myokine 
that mediates this retrograde messaging from muscle to motor neurons. 
 
1.3.4 PGC-1α stability 
PGC‐1α1 protein has a short half‐life of approximately 30 minutes. Several studies have 
demonstrated that PGC‐1α1 is a substrate for degradation by the ubiquitin-proteasome 
system [83, 87, 88, 107, 108]. Ubiquitin-mediated proteolysis is an important regulatory 
mechanism involved in different cellular processes such as development, cell cycle control, 
and transcription [109]. The E3 ubiquitin ligases recognize substrates for ubiquitylation. So 
far, different laboratories have reported some E3 ubiquitin ligases, which can target PGC‐
1α1 for degradation. The function of E3 ligases in the ubiquitylation system is to determine 
substrate specificity via interaction with target proteins and transfer of ubiquitin to them. 
Different E3 ligases bind to different PGC‐1α1 regions to target it for degradation. Some of 
these ligases recognize a domain in the N-terminus of PGC‐1α1 that targets this protein for 
degradation and has a code for ubiquitylation. Some other ligases recognize a C-terminal 
domain as a code to process ubiquitylation. 
It has been shown that the multi-subunit E3 ligase SCFFbw7 complex promotes PGC‐1α1 
ubiquitylation and degradation. SCFFbw7 recognizes a phosphodegron consisting of four 
amino acids in the N-terminus of PGC‐1α1 protein. This phosphodegron is phosphorylated 
by GSK3β and p38MAPK [83] and is conserved in the PGC-1 family, suggesting that 
SCFFbw7 might also be an E3 ligase for PGC-1β. However, the importance of this 
ubiquitylation by Fbw7 in PGC‐1α target gene expression and energy metabolism is still 
not clear. RNF34 is another E3 ligase controlling PGC‐1α degradation with regulation of 
the endogenous PGC‐1α protein levels, target gene expression, and cellular respiration 
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capacity in brown fat cells. The effects of RNF34 are independent of change in PGC‐1α 
expression and disappear with expression of a mutant RNF34 that misses its ligase activity 
[88]. In contrast to SCFFbw7, the C-terminal half (amino acids 350 to 797) of PGC‐1α 
interacts with RNF34 and targets this protein for degradation. 
Although PGC‐1α1 is an intrinsically disordered protein (IDP) that degrades fast by the 
20S proteasome [110], some studies have shown that binding of PGC-1α1 to some of its 
protein partners like ERRγ can induce conformational changes in PGC-1α1 structure that 
might rescue this protein from degradation [111]. 
 
1.4 THE ROLE OF PGC-1α IN METABOLIC REGULATION IN 
DIFFERENT TISSUES 
1.4.1 PGC-1α function in skeletal muscle 
Skeletal muscle (about 40% of the body weight of a lean individual) is a tissue with 
fundamental role in mobility, energy balance and metabolism in the body. Interestingly, 
PGC-1α expression increases both in human and rodent muscle after exercise [112, 113]. A 
summary of PGC-1α function in skeletal muscle in response to different physiological cues 
is shown in Figure 6. In skeletal muscle especially oxidative slow-twitch fibers, all PGC-1α 
isoforms can be expressed in response to exercise to increase mitochondrial content and 
oxidative phosphorylation capacity. It has also been shown that increasing muscle PGC-1α 
expression (driven by muscle creatine kinase promoter) will protect from sarcopenia (loss 
of muscle mass and strength) and metabolic diseases during aging. This protection happens 
through increase in mitochondrial gene expression and improved metabolic responses such 
as increased insulin sensitivity in aged mice. Moreover, overexpression of PGC-1α in 
mouse model leads to fiber type switch toward slow-twitch fibers rich in mitochondria [43], 
increased angiogenesis [114] and improvement in muscle function and motor coordination 
[115]. All these studies emphasize the importance of PGC-1α in the adaptation of skeletal 
muscles to physical activity. On the other hand, PGC-1α skeletal muscle-specific knockout 
mice show a shift from oxidative fibers toward more glycolytic fibers and exhibit reduced 
endurance capacity and increased inflammation markers after treadmill running [116]. 
Nevertheless, there are some other studies that suggest PGC-1α expression in muscle is not 
strictly required for adaptation to exercise [93, 113]. These studies were done using global 
PGC-1α knockout or skeletal muscle specific PGC-1α knockout mice. These mice can 
perform similar voluntary exercise (not forced exercise) and run the same distance as their 
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wild-type controls. This discrepancy in the results can be due to the differences in targeting 
strategy in generation of the whole body and muscle specific PGC-1α knock out mice. The 
global PGC-1α knockout mice show a complex phenotype since these animals are 
characterized by elevated metabolic rates and hyperactivity [71]. Moreover, we should also 
consider the functional redundancy between PGC-1α and PGC-1β in maintaining skeletal 
muscle function.  
Besides physical activity, calorie restriction is another challenge that will alter oxidative 
metabolism in muscle. This stimulus also leads to the induction of PGC-1α expression that 
is necessary for increase in mitochondrial mass [117].  
All these beneficial effects of PGC-1α in metabolic control in the muscle has promoted this 
protein as a good candidate for treatment of metabolic disorders and muscle wasting 
disorders such as sarcopenia and Duchene muscular dystrophy (DMD) [46] or cancer. 
Overexpression of PGC-1α can ameliorate DMD and is associated with improvement of 
muscle injury. This phenomenon happens through increase in mitochondrial biogenesis and 
oxidative phosphorylation [118]. Moreover, overexpression of Sirt1, PGC-1α activator, also 
ameliorates DMD in the mouse model with this disease (mdx mice) by increasing 
mitochondrial biogenesis, fiber type switching toward oxidative fibers, and inducing genes 
regulating neuromuscular junction [119].  
 
Figure 6. PGC-1αs regulatory function in skeletal muscle. Different physiological cues trigger 
specific gene programs to modulate cellular adaptation in skeletal muscle to diverse challenges. 
These gene programs modulate mitochondrial biogenesis, glucose utilization, fiber type switching, 
angiogenesis and NMJ properties to improve skeletal muscle function and performance. CaN 
(Calcineurin), CaMK (Calmodulin-dependent protein Kinase), CdK (Cyclin-dependent Kinase). 
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1.4.2 PGC-1α function in liver 
PGC-1α expression is induced in liver upon fasting. This coactivator shows a pivotal 
function in the regulation of gluconeogenesis and hepatic expression of mitochondrial 
genes in liver. This regulation by PGC-1α occurs through interactions with transcription 
factors such as FOXO1 [68], HNF-4α [73] and glucocorticoid receptors and increases in the 
transcription of genes such as phosphoenolpyruvate carboxy kinase (PEPCK) and glucose 
6-phosphatase (G6Pase). PGC-1α induction by fasting happens both through glucagon and 
glucocorticoids [73, 120], which are the main signaling hormones during fasting and 
deacetylation by Sirt1, which leads to increase in its transcriptional activity [121]. This tight 
regulation balances the hepatic glucose production according to fuel supply and demands. 
Impaired control over gluconeogenesis will affect the whole-body glucose homeostasis. 
Indeed, elevated hepatic glucose production is recognized as one of the consequences of 
hepatic insulin resistance [122]. Reduced hepatic insulin sensitivity results in increased 
hepatic lipogenesis and hepatic steatosis [123]. 
 
1.4.3 PGC-1α function in brain 
PGC-1α is expressed in different cell types of the brain, such as dopaminergic cells [124]. 
In addition to regulating mitochondrial biogenesis and oxidative phosphorylation, this 
coactivator is also implicated in the activation of antioxidant defense genes in the brain 
[48]. Since neural tissues are very dependent on mitochondrial function, a lack of PGC-1α 
expression has been suggested to contribute to many neurodegenerative disorders such as 
Alzheimer’s, Parkinson’s and Huntington’s diseases [52, 125, 126]. In all of these 
disorders, reduced mitochondrial function due to reduced levels of PGC-1α expression has 
been reported, making PGC-1α a potential therapeutic target for neurodegenerative 
diseases. Moreover, we have recently reported that activation of skeletal muscle PGC-1α1 
can have protective effect against stress-induced depression [105]. The mechanism that 
mediates this muscle to brain crosstalk is through skeletal muscle detoxification of 
kynurenine, which is in this way converted to kynurenic acid. Kynurenine aggregation in 
the brain has been connected to neuroinflammation and depression. Activation of the PGC-
1α1-PPARα/δ pathways in skeletal muscle induces kynurenine aminotransferases 
expression, the enzymes responsible for the conversion of kynurenine to kynurenic acid. 
Since kynurenic acid cannot freely cross the blood-brain barrier, it remains in the periphery 
thus reducing central kynurenine accumulation and associated effects. 
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1.5 MOLECULAR ASPECTS OF ADIPOSE TISSUE 
Vertebrates are able to store energy in the form of lipid droplets in specialized cells known 
as adipocytes [127]. From a broad metabolic perspective, adipocytes tend to be grouped 
into 3 types: white adipocytes, brown adipocytes, and beige/brite adipocytes. White 
adipocyte store lipids, which can later be released as fatty acids. On the other hand, brown 
adipose tissue (BAT) stores lipids as fuel for thermogenesis [128, 129]. BAT is highly 
vascularized and contains multilocular lipid droplets. Brown adipocytes exert their function 
in thermogenesis through uncoupling protein 1 (UCP1), which is located in the 
mitochondria. Prolonged cold exposure or adrenergic signaling induces other UCP1+ cells 
located in white fat depots. These cells are called beige/brite adipocytes and have similar 
morphology to brown adipocytes but distinct gene expression profiles and have lower basal 
level of UCP1 expression [130]. Additionally, beige/brite adipocytes have been shown to 
promote thermogenesis through UCP1-independent mechanisms [131]. 
 
1.5.1 Developmental origins of brown adipose tissue 
Brown adipocytes exist in both rodents and newborn humans in paraspinal, intrascapular 
and interscapular regions. In rodents, brown adipocytes that are located in the interscapular 
regions develop during embryogenesis. BAT share the same precursor cells with skeletal 
muscle and they both derive from PAX7+/Myf5+ stem cells during development [132, 133] 
and their divergence occurs between days 9.5 and 12.5 of mouse gestation [134] (Figure 6). 
In contrast, white and beige/brite precursor cells derive from PAX7-/Myf5- stem cells. It has 
been shown that beige/brite adipocytes that have appeared in response to cold exposure can 
return to the morphology and gene expression pattern of white adipocyte after exposure to 
warm condition through trans-differentiation [135]. 
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Figure 7. Origin of different adipocytes. Brown adipocyte has the same origin as myocyte and 
comes from Pax7+ /Myf5+ stem cells. White and beige adipocytes drive from Pax7- /Myf5- stem 
cells through distinct precursor cells. Beige precursor cells differentiate to active beige adipocytes 
by cold exposure and when the challenge is removed they become inactive again with morphology 
of white adipocytes.  
 
1.5.2 Transcriptional regulation of thermogenesis through UCP1 
β-adrenergic signaling and cAMP are the main regulators of thermogenesis in brown 
adipocytes via strong induction of UCP1 expression and activity. Indeed, cellular cAMP 
variations are sensed by protein kinase A (PKA) and result in the activation of p38MAPK 
and CREB [136-138]. This in turn leads to the activation of PGC-1α1, which causes a 
subsequent increase in UCP1 expression.   
In response to cold exposure, PGC-1α1 regulates gene expression of transcription factors 
such as PPARα [139], PPARγ [40], Retinoid X receptors (RXR), NRF1 and thyroid 
receptors [140] to positively regulate thermogenesis via UCP1. Furthermore, applying 
specific agonists for some of these transcription factors (that are nuclear receptors) will lead 
to induction of UCP1 in adipose tissue. For example, rosiglitazone, a PPARγ agonist, 
induces PGC-1α1 expression and causes PRDM16-mediated adipose tissue browning [139]. 
Finally, another mechanism that results in activation of adaptive thermogenesis is mediated 
by the induction of PPARα/δ signaling pathways by lipolytic products [141]. 
 
1.5.3 PGC-1α function in thermogenesis in brown adipose tissue 
PGC-1α expression is highly induced in brown adipocytes during cold exposure to 
positively control the expression of genes participating in thermogenic program such as 
UCP1 and deiodinase-2 (Dio2) [40]. Indeed, PGC-1α acts at the promoter of these genes in 
a complex with diverse transcription factors and nuclear receptors such as thyroid hormone 
receptors, PPARγ, CREB or activating transcription factor-2 (ATF-2) to activate 
thermogenesis [137, 142]. In line with this, one of the available PGC-1α knockout mouse 
models [71] shows cold-intolerance and cannot induce UCP1 expression in response to cold 
exposure. In contrast, a different PGC-1α knockout mouse model [70] responds to cold 
exposure normally through increased UCP1 expression. The differences in the phenotypes 
observed in these two models are likely to be the result of different gene targeting 
strategies. The strategy used by Lin et al [71] deletes exons 3-5 of the PGC-1α gene. The 
gene continues to be transcribed, but the resulting mRNA encodes (at most) for a relatively 
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short peptide encoded by exons 1 and 2. In addition, this strategy interferes with the 
expression of most known PGC-1α isoforms. On the other hand, in the model generated by 
Leone et al [70] there is no exon deletion but a duplication of exon 3. This leads to a frame 
shift in the resulting mRNA, that still encodes a protein remarkably similar to NT- PGC-1α, 
one of the PGC-1α isoforms. Importantly, NT- PGC-1α has been shown to be sufficient to 
activate thermogenesis [143]. 
Increasing adaptive thermogenesis has been suggested as an attractive anti-obesity 
therapeutic strategy. To this end, induction of PGC-1α activity can be a useful tool to 
protect against obesity. Identifying mechanisms and molecules that can increase PGC-1α 
activity is an interesting subject for development of new therapies.     
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2 AIMS OF THE THESIS 
The overall goal of the work presented in this thesis was to characterize the 
structure/function relationship in the PGC-1α family of transcriptional coactivators. We 
aimed to identify the contribution of these proteins to transcriptional regulation especially 
in skeletal muscle and brown adipocytes. 
 
Specific aims were as follow: 
• To identify protein partners for the different PGC-1α isoforms in order to elucidate 
how PGC-1α coactivators regulate target gene expression and understand the 
molecular pathways that they might regulate. 
 
• To identify target genes of each PGC-1α isoform and delineate the molecular 
pathways that they regulate in skeletal muscle. 
 
• To identify molecules that activate PGC-1α1 in brown adipocytes.  
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3 RESULTS AND DISCUSSION 
3.1 IDENTIFICATION OF PGC-1a ISOFORM-ASSOCIATED PROTEINS 
(PAPER I) 
Transcription of a single PGC-1α gene produces different isoforms (e.g. PGC-1α1 to α4) 
with different biological functions. The mechanism of action of PGC-1α1 is well known 
and it interacts with different chromatin remodeling factors, transcription factors and the 
mediator complex through different structural domains (Figure 4). In paper I, we 
characterized the nuclear interactome for each PGC-1α isoform, with an emphasis on 
transcriptional regulators that they recruit to regulate gene expression. Interestingly, we 
observed despite the differences in the structure of different PGC-1α isoforms, they can 
recruit versions of the mediator, histone acetyltransferase, and splicing complexes. For 
some of these interactions we noticed isoform specificity. For example, we identified that 
KAT8 (member of the HAT complex) has the preference to interact with novel PGC-1α 
isoforms or that TADA1 just interacts with PGC-1α4. To date, no histone deacetylase 
proteins have been shown to interact with PGC-1α1. However, for the first time we show 
that all PGC-1α coactivators can associate with histone deacetylases and related repressor 
complexes. This finding provides a novel mechanism to explain the negative effect of PGC-
1α isoforms on gene expression [95, 96, 144].   
Moreover, we found that all PGC-1s were able to efficiently interact with the mediator 
complex even in the absence of the RS/RRM domain of PGC-1α1 that was reported to be 
necessary for this interaction [58]. Furthermore, we identified members of the spliceosome 
complex in association with the PGC-1α isoforms. This data is in line with our previous 
study demonstrating that all PGC-1α variants can affect target gene splicing [95]. We 
identified some of the SRSF (serine/arginine splicing factors) factors in all PGC-1α 
complexes. Some of these SRSF factors were previously reported just interacting with 
PGC-1α1 [63]. We also found the transcription factors interacting with each PGC-1α 
variant. Some of these TFs, such as TFAM, HCF, and YY1 proved to interact with all 
PGC-1α variants. Additional TFs with high affinity for all PGC-1α isoforms were PBX1 
(pre-B-cell leukemia transcription factor), SP1, SP2, and ATF1 (activating transcription 
factor). 
To elucidate how PGC-1α isoforms regulate target gene expression in skeletal muscle, we 
performed an integrated analysis of each PGC-1α interactome and transcriptome. With this 
approach, we could identify several novel isoform-associated transcription factors with 
binding sites present in the promoters of the corresponding target genes, and therefore 
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propose novel modes of action for each PGC-1α isoform. From the multi-omics analysis, 
we determined an overlap between the PGC-1α-interacting TFs and the corresponding 
predicted TFBS (transcription factor binding sites) in their target gene promoters. We could 
validate this approach by the identification of several previously known PGC-1α-interacting 
TFs (e.g. RXR, ERR, HNF4), and also identify additional TF partners. Most notably, 
among the predicted TFs for each PGC-1α isoform, the functional relationship between 
CREB and PGC-1α1 has been extensively reported [45, 120], but the interaction between 
these two proteins had never been shown. CREB was also present in the PGC-1α3 and 
PGC-1α4 complexes. Interestingly, PGC-1α4 has been shown to be downstream of beta-
adrenergic signaling in skeletal muscle [96], which also results in CREB activation [145]. 
 
3.2 PGC-1a1 FORMS HETERODIMERS WITH ALL PGC-1a ISOFORMS 
(PAPER I) 
PGC-1α1 has been shown to homodimerize that leads to protein stabilization and enhanced 
recruitment of protein partners [59, 111], and we also observed the presence of hPGC-1α in 
all PGC-1α isoform complexes. These observations inspired us to investigate the existence 
of isoform heterodimers. To this end, we expressed and purified FLAG-PGC-1α1 in insect 
cells and used it to perform protein-protein interaction assays with GST-fusions of all 
isoforms. Strikingly, apart from the expected FLAG-PGC-1α1: GST-PGC-1α1 
homodimerization, we determined FLAG-PGC-1α1 heterodimerizes with PGC-1α2, α3, 
and α4 (Figure 7). Although we don’t know the interaction interfaces in formation of the 
different heterodimers, these results indicate the existence of previously unknown PGC-1α 
dimers. 
 
Figure 7: PGC-1α isoforms dimerization. PGC-1α1 can heterodimerize with novel PGC-1α 
isoforms. 
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3.3 REGULATION OF TARGET GENE EXPRESSION BY PGC-1a1 DEPENDS 
ON THE OTHER ISOFORMS (PAPER I) 
We performed global analysis of gene expression upon ectopic PGC-1α1 expression in 
wild-type myotubes or myotubes with genetic deletion of all PGC-1α variants to determine 
to what extent PGC-1α1 is able to regulate target gene expression in muscle cells. 
Interestingly, we observed that muscle development, muscle cell differentiation and 
myofibril assembly are processes regulated only in the presence of all PGC-1α isoforms 
(WT background). On the other hand, PGC-1α1 alone without the help of other isoforms 
regulates processes linked to energy metabolism and protein transport. Strikingly, these 
results suggest that interaction of PGC-1α1 with the other	 isoforms mainly drives gene 
programs affecting skeletal muscle cell differentiation and development, while PGC-1α1 
alone functions in cellular energy metabolism.  
From the multi-omics analysis, we have predicted the interaction of PGC-1α2 with FOX 
family of transcription factors (FOX-M, FOX-N and FOX-K). These transcription factors 
are involved in the regulation of muscle cell proliferation and muscle development [146, 
147] that supports our observation that novel PGC-1α isoforms have a role in regulation of 
genes related to muscle development.  
Taken together, our results provide novel mechanisms by which PGC-1α	coactivators can 
regulate gene expression. It will be interesting to characterize if different PGC-1α	
heterodimers have novel biological activities or if their heterodimerization illustrate some 
of the known biological effects of PGC-1α	in distinct tissues.  
 
3.4 PGC-1a ISOFORMS DISPLAY DISTINCT PROTEIN STABILITY (PAPER II) 
PGC-1α1 has a short half-life and is degraded fast by ubiquitin-proteasome system. To 
determine whether the same degradation pathway targets all PGC-1α isoforms, myotubes 
with ectopic expression of each PGC-1α isoforms were treated with proteasome inhibitor 
MG132. Interestingly, all PGC-1α proteins accumulate to different levels after MG132 
treatment. This means they all degrade through the ubiquitin-proteasome pathway. 
Strikingly, we observed different degradation patterns for PGC-1α isoforms after inhibition 
of protein synthesis by cycloheximide. PGC-1α2 and PGC-1α3 exhibited a half-life similar 
to PGC-1α1 (~ 30 min), but PGC-1α4 showed higher stability with a remarkably long half-
life (~240 min). 
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3.5 IDENTIFICATION OF REGULATED GENE TARGETS/PATHWAYS BY 
EACH PGC-1a ISOFORMS (PAPER II) 
We performed global gene expression analysis using exon arrays in myotubes expressing 
each PGC-1α isoform to identify genes regulated by each isoform and identified a large 
number of specific PGC-1α isoform target genes. We found the highest number of 
coregulated genes between isoforms PGC-1α1 and α4 and between PGC-1α2 and α3. Since 
PGC-1α2 and PGC-1α3 lack part of the activation and repression domains present in the 
canonical isoform (PGC-1α1) (Figure 5), they produce a distinct cluster of target genes 
from PGC-1α4 that shows more similarity to PGC-1α1. This suggests that the 
transcriptional activity of PGC-1α isoforms is mainly dictated by the conservation of the N-
terminal activation domain compared to the RS/RRM motif.  
In addition, we performed a comprehensive pathway and network analysis to predict 
biological functions linked to the transcriptional programs regulated by each PGC-1α 
isoform. We validated some of the selected genes identified from each pathway by qRT-
PCR. Once again, this analysis showed the involvement of PGC-1α1 in mitochondrial 
biology and oxidative metabolism. PGC-1α2 target genes in myotubes were associated with 
cholesterol biosynthesis and regulation of inflammatory processes. The pathways identified 
for PGC-1α3 were linked to development and cell cycle control. Finally, PGC-1α4 
regulates muscle mass and hypoxia-driven angiogenesis in skeletal muscle. We also found 
PGC-1α4 as a negative regulator of hypoxia-inducible factor-1α signaling (and also 
involved in cancer signaling). Because PGC-1α isoforms have distinct protein accumulation 
(for similar mRNA levels), we were concerned that the different target gene sets could be a 
reflection of the differences in PGC-1α isoform stability. Therefore, we validated target 
gene specificity upon increased expression of each PGC-1α variant in myotubes. We 
observed increased protein accumulation of PGC-1α1, PGC-1α2 and PGC-1α3 but not 
PGC-1α4. Subsequently, we observed the specificity of PGC-1α target genes remained 
unaffected. 
When we compared the results in our study with previously published PGC-1α variant 
target gene data [96], we found both studies (exon array and Affymetrix gene array) were 
equally efficient in the identification of PGC-1α1 target genes. However, this was different 
for other isoforms especially PGC-1α2 and PGC-1α3, for which we identified over 1000 
regulated genes by either coactivator compared to less than 100 regulated genes identified 
by Affymetrix gene array. For PGC-1α4 the top canonical pathways observed in our study 
did not show a significant overlap with Affymetrix gene array.  
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3.6 PGC-1a ISOFORMS SELECTIVELY AFFECT THE SPLICING EVENTS IN 
MYOTUBES (PAPER II) 
In paper II, we observed that expressing each PGC-1α isoform leads to a different pattern of 
exon alignment for some target genes. This indicates that PGC-1α isoforms can affect target 
gene splicing. We used several complementary bioinformatics tools and determined a large 
number of genes with different splicing patterns modulated by different PGC-1α variants. 
Later, we validated some of these different splicing events under control of PGC-1α 
isoforms via targeted qRT-PCR. For example, we show that PGC-1α2 and PGC-1α3 affect 
Ddx27 isoform expression, while PGC-1α1 and PGC-1α4 regulate Osbpl1a and Ndrg4 
isoform expression. 
We found that the splicing events by PGC-1α4 in myotubes were similar to what we 
observed for PGC-1α1. Splicing events regulated by PGC-1α2 were also similar to PGC-
1α3. Therefore, we suggest that conservation of the activation domain in their structures 
can impact defining both gene programs and also the splicing process during mRNA 
maturation. 
Furthermore, we could validate some of the splicing procedures, which we observed in 
vitro for PGC-1α1 and PGC-1α4 in vivo on muscle-specific transgenic mouse lines for 
these two isoforms. We observed changes in both gene expression and protein levels of 
short C-terminal isoform of Osbpl1a in skeletal muscle of both transgenic models. Specific 
expression of PGC-1α1 promoted increase in the mRNA level of Ndrg4 variants derived 
from the internal promoter region while in PGC-1α4 transgenic mice we observed the 
increase in all Ndrg4 isoforms regardless of the promoter of origin. In contrast to the results 
from transcript level, the protein content of Ndrg4 short isoforms in muscle of both 
transgenic mice was reduced. The precise mechanism of how coactivators regulate co-
transcriptional splicing is under investigation. 
Taken together our results in paper II show that PGC-1α isoforms regulate target gene 
splicing and affect the expression of specific exon composition of their corresponding 
transcripts. 
 
3.7 IDENTIFICATION OF SMALL MOLECULE PGC-1a1 
STABILIZERS/ACTIVATORS IN BROWN ADIPOCYTES (PAPER III) 
As we discussed in this thesis, PGC-1α1 is one of the main modulators of metabolism in a 
tissue-specific manner. Several studies have tried to increase the expression of PGC-1α1 
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and use it as a therapeutic approach in treatment of metabolic disorders [148, 149]. But the 
short half-life of this protein is an obstacle to overcome. In Paper III, we developed a cell-
based screening system to identify stabilizers of PGC-1α1. To this end, we generated a 
stable cell line expressing an EGFP-PGC-1α1 fusion protein and performed high-
throughput screening using a small compound library. After treating cells with compounds, 
changes in fluorescence localization and intensity of the fusion protein were analyzed using 
a fully automated microscopy system. Among the 114 primary hits we decided to continue 
with the validation of 79 compounds in brown adipocytes. After treatment of fully 
differentiated brown adipocytes with different compounds, DMSO (negative control) and 
isoproterenol (positive control), primary validation was done by qRT-PCR analysis of 
PGC-1α1 target gene activation. Validation by qRT-PCR was done for some of the known 
PGC-1α1 target genes involved in mitochondrial biogenesis, browning, non-shivering 
thermogenesis, antioxidant defenses and oxidative phosphorylation. We included the 
general proteasome inhibitor MG132 in our treatments to compare compound effects with 
maximal protein stabilization. Brown adipocytes treated with MG132 showed reduced 
expression of most of the genes we analyzed. This difference in gene expression pattern by 
MG132 from our selected compounds indicates that these compounds were not general 
inhibitors of the proteasome. With this approach we excluded compounds with general 
proteasome inhibitory effects that have no specific impact on PGC-1α1 activation and 
biological effects. From all the target genes we analyzed, after treatment with the different 
compounds, UCP1 showed the highest induction. 19 compounds, among all the validated 
compounds, showed at least 2-fold induction in UCP1 expression.  
Next, we performed a second validation of compounds in brown adipocytes, on endogenous 
PGC-1α1 protein level by western blot. We found that 45 compounds induced PGC-1α1 
accumulation. In summary, after both validations we found that 17 of the validated 
compounds increased both PGC-1α1 protein accumulation and UCP1 expression. We chose 
five of these compounds (AM31, AM73, AM79, AM80 and AM89) that induced UCP1 
expression over 5-fold and also stabilized PGC-1α1 protein for further analysis.  
To explore if the selected compounds can impact biological activity of PGC-1α1, we 
measured cellular respiration rate in brown fat cells after treatment with these compounds. 
In agreement with the observed increase in UCP1 expression we reported an elevation in 
basal level of mitochondrial respiration for all select compounds except AM89. The basal 
respiration increase remained even after addition of an inhibitor of ATP synthase 
(oligomycin). This indicates an increase in uncoupled respiration rather than ATP turnover, 
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likely through increase in UCP1 expression. Only AM89 shows slight increase in maximal 
respiration, which could be the effect of more mitochondria and/or mitochondrial protein. 
To understand the mechanism of action of selected compounds, we performed a broad gene 
analysis in brown adipocytes treated with AM73 and AM80. Interestingly, we found 
regulated pathways by AM73 were canonical PGC-1α1-regulated pathways such as BAT 
cells differentiation, response to hypoxia, insulin signaling and carbohydrate metabolism. 
We performed a DiRE analysis to identify the transcriptional pathways modulating genes 
differentially expressed upon treatment with AM73 or AM80. We found the transcription 
factor binding sites for many previously known PGC-1α1 protein partners including 
C/EBP, MEF2, PPARα, HNF, NRF2, XBP1, and SREBP1 proteins. All these transcription 
factors are expressed in adipocytes and it is possible that PGC-1α1 is the key factor in 
modulating their respective target genes.  
Moreover, to compare the gene expression profile differences upon treatment of 
AM73/AM80 with another known inducer of browning, we used the previously published 
data from cAMP-treated brown adipocytes. cAMP is a classical inducer of thermogenic 
program in brown adipocyte [150]. We analyzed the regulated pathways with each reagent 
separately, the coregulated genes/pathways with both cAMP and AM73, and contra-
regulated genes/pathways by these two reagents. For example, we found both cAMP and 
AM73 induce blood vessel development. Strikingly, brown fat cell differentiation and 
oxidation/reduction were the main regulated pathways with AM73 alone. We performed the 
same analysis for AM80 as well. The specific gene signature for AM73 and AM80 compare 
to cAMP indicates these compounds exert their functions distinct from cAMP induced 
pathways. 
The exact mechanisms of action of PGC-1α1 activators are still unclear. Although we show 
that the select compounds are not just general inhibitors of the ubiquitin-proteasome system 
(through different gene expression profile than MG132), they still might be general 
inhibitors of E3-ubiquitine ligases, which are not specific to PGC-1α1. Therefore, they 
could also be stabilizers of other proteins leading to unwanted effects. Moreover, some 
compounds that are just PGC-1α1 protein stabilizers, had small or no impact on target gene 
expression, which might induce PGC-1α1 stabilization by post-translational modifications 
(PTMs). In contrast, some compounds that are just UCP1 expression inducers, with no 
changes in PGC-1α1 protein accumulation, might induce UCP1 expression via PGC-1α1-
independent mechanisms or PTMs. This results in a more target gene activation without 
increase in total PGC-1α1 protein accumulation. We should also consider the fact that 
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PGC-1α1 is among intrinsically disordered proteins that degrades fast [151]. In theory the 
interaction of PGC-1α1 with small compounds could stabilize PGC-1α1 protein by 
conformational changes that make it less susceptible for degradation [152]. 
Finally, we should consider that systemic activation of PGC-1α1 might not have beneficial 
effects in treatment of all types of metabolic disorders. In liver, increase in PGC-1α1 
activity leads to higher glucose output, which is not a desirable effect in treatment of type 2 
diabetes and obesity. However, the specificity of PGC-1α1 function depends also on the 
presence of specific transcription factors and on post-translational modifications of PGC-
1α1 in tissue specific manner. Although this quickly confuses the prediction of general 
activation of PGC-1α1, it also provides the possible activation of a particular gene program 
such as mitochondrial genes and fatty acid oxidation whereas leaving other networks like 
gluconeogenesis in the liver unaffected. Furthermore, development of chemicals that could 
be targeted to particular tissues (and not the liver) might be another solution to avoid the 
unwanted effect of PGC-1α1 activation in the liver. Indeed, a recent study [86], used 
chemical inhibition of PGC-1α acetylation by GCN5 to reduce activity of PGC-1α as a tool 
to reduce blood glucose levels in type 2 diabetic mice.  
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
The general aim of the studies included in this thesis was to investigate the 
structure/function relationships in the PGC-1 family of transcriptional coactivators. To this 
end, we have used biochemical and molecular techniques to identify the protein partners of 
different PGC-1α isoforms, their respective target genes, and to characterize their 
mechanisms of action. We observed that all PGC-1α isoforms can play a positive role in the 
regulation of gene expression at the transcriptional level (paper I). All the isoforms interact 
with transcriptional coregulators such as the mediator complex, histone acetyltransferases, 
and different splicing factors (albeit to different degrees and in an isoform-specific 
manner). As it was presented in the results of paper I and paper II, we demonstrate all PGC-
1α isoforms are involved in regulating gene-splicing events. Distinct PGC-1α isoforms 
promote a diverse exon composition of their target transcripts (paper II). In this thesis we 
used bioinformatic tools for the prediction of target genes and pathways, which are 
regulated by each PGC-1α variant (paper II). We further combined the identified target 
genes in this study with obtained proteomics data from paper I to exploit the mechanism of 
function of these proteins. Taken together, the observations from paper I and paper II 
helped us identify the predicted transcription factors for each PGC-1α isoform. Strikingly, 
for the first time we identify the heterodimerization of PGC-1α1 with PGC-1α2, α3 and α4 
(paper I). This finding might change the way we evaluate PGC-1α1 function in diverse 
tissues because some of the known biological effects of PGC-1α1 might be through its 
interaction with other isoforms. For example, our findings in paper I indicate that PGC-1α1 
function on the broad pathway of skeletal muscle development, only works in the presence 
of other isoforms.  
Furthermore, we observed that PGC-1α isoforms have different protein stability (paper II) 
and in paper III we developed a screening platform to increase PGC-1α1 accumulation and 
activity in brown adipocyte. We identified several compounds that increase PGC-1α1 
protein levels and the expression of some of its target genes. These small molecules also 
increased basal mitochondrial respiration in brown adipocytes through induction of UCP1 
expression. These findings could be important for developing new therapeutic tools for the 
treatment of metabolic disorders and skeletal muscle wasting.  
As it has been broadly shown, PGC-1αs are important transcriptional regulators in 
metabolism to balance the energy supply and demand. According to the prominent role of 
PGC-1αs in these cellular processes, increasing PGC-1α activity is gaining great attention 
for treatment of metabolic disorders. Inducing PGC-1α activity in brown fat and switching 
 30 
higher lipid storage to more heat generation might be an interesting tool in treatment of 
obesity. Furthermore, the effect of PGC-1α in the regulation of mitochondrial biogenesis, 
oxidative phosphorylation and glucose metabolism renders this molecule as a target for 
treatment of neurodegenerative disorders (Parkinson disease, Huntington and Alzheimer 
diseases), cancer, type 2 diabetes and skeletal muscle wasting diseases such as Duchene 
muscular dystrophy. 
In developing new therapies by targeting PGC-1α activation, we should consider that 
systemic activation of PGC-1α might not have beneficial effects in all tissues. Tissue 
specific function of PGC-1α should be considered in designing new therapies. Our findings 
about protein partners and regulated target genes by each PGC-1α isoform can be a useful 
resource for understanding the mechanism of function of PGC-1 family and improve the 
methods, which will be applied in clinical research in the future. 
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